Patients who have PAD are known to have an elevated risk (1 in 5) of major adverse limb and cardiovascular events following lower extremity revascularisation, despite antiplatelet therapy. The previously published VOYAGER PAD (NCT02504216) trial demonstrated that rivaroxaban (a non-vitamin K antagonist oral anticoagulant) combined with usual care lowered the risk of first events [3]. Dr Rupert Bauersachs (Klinikum Darmstadt, Germany) presented results of a pre-specified analysis aimed to assess the impact on both first and subsequent ischaemic events in this population [1].
VOYAGER PAD randomised 6,564 participants with PAD who had recently undergone lower extremity revascularisation to receive either 2.5 mg rivaroxaban twice daily (n=3,286) or a matching placebo (n=3,278) in addition to usual care. The current analysis evaluated all components of the primary endpoint (i.e. myocardial infarction, ischaemic stroke, cardiovascular death, acute limb ischaemia, or major limb amputation due to a vascular cause) as well as additional vascular events (incl. venous thromboembolism and peripheral revascularisations).
A total of 4,714 first and subsequent events occurred among the entire study population in VOYAGER PAD. Of the 1,614 first events, 745 occurred in the rivaroxaban group, and 869 in the placebo group. Rivaroxaban reduced the incidence of first events by 15%. Of the 3,100 remaining subsequent events, 1,659 occurred in the placebo group as compared with only 1,441 in the rivaroxaban group.
- Bauersachs RM. Reductions in Total Ischemic Events with Rivaroxaban in Patients with Symptomatic Pad after Revascularization: The VOYAGER PAD Trial. Abstract 406-13, ACC 2021 Scientific Session, 15-17 May.
- Bauersachs RM, et al. J. Am. Coll. Cardiol. 2021;16 May.
- Bonaca MP, et al. N Engl J Med 2020;382:1994-2004.
Posted on
Previous Article
« Similar outcomes fractional flow reserve and angiography-guided revascularisation Next Article
Dapagliflozin fails to show a significant protective effect in COVID-19 »
« Similar outcomes fractional flow reserve and angiography-guided revascularisation Next Article
Dapagliflozin fails to show a significant protective effect in COVID-19 »
Table of Contents: ACC 2021
Featured articles
Electrophysiology
Favourable outcomes with transcatheter atrial appendage occlusion
Etripamil nasal spray significantly improves PSVT-related symptoms
Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
Heart Failure and Cardiomyopathy
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Novel use of ivabradine in reversible cardiomyopathy
Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy
Interventional and Structural Cardiology
Men and women benefit equally from early aspirin withdrawal following PCI
Similar outcomes with fractional flow reserve and angiography-guided revascularisation
TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI
Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI
Ischaemic Heart Disease
No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial
Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation
Moderate hypothermia not superior to mild hypothermia following out-of-hospital cardiac arrest
Better outcomes with invasive strategy if anatomic complete revascularisation is possible
Prevention and Health Promotion
STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids
Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia
Health equity and the role of the cardiologist: 7 priorities to consider
COVID-19
Dapagliflozin fails to show a significant protective effect in COVID-19
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Valvular Heart Disease
Apixaban outcomes similar to current standard of care following TAVR
Preliminary results encouraging for EVOQUE tricuspid valve replacement
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy